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The coronavirus disease 2019 (COVID-19) is an emerging pandemic challenge. Acute respiratory distress
syndrome (ARDS) in COVID-19 is characterized by a severe cytokine storm. Patients undergoing glucocorticoid
(GC) replacement therapy for adrenal insufficiency (AI) represent a highly vulnerable group that could develop
severe complications due to the SARS-CoV-2 infection. In this review, we highlight the strategies to avoid an
adrenal crisis in patients with AI and COVID-19. Adrenal crisis is a medical emergency and an important cause of
death. Once patients with AI present symptoms of COVID-19, the dose of GC replacement therapy should be
immediately doubled. In the presence of any emergency warning signs or inability to administer oral GC doses,
we recommend that patients should immediately seek Emergency services to evaluate COVID-19 symptoms and
receive 100 mg hydrocortisone by intravenous injection, followed by 50 mg hydrocortisone intravenously every
6 h or 200 mg/day by continuous intravenous infusion.
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’ INTRODUCTION
The coronavirus disease 2019 (COVID-19), caused by the
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), is an emerging pandemic (1). In severe cases, patients
with COVID-19 develop a type of acute respiratory distress
syndrome (ARDS) approximately 8–9 days after symptom
onset (2). The SARS-CoV-2 infection triggers a local immune
response in lung cells, recruiting macrophages and mono-
cytes. SARS-CoV-2 induced-ARDS is characterized by a severe
cytokine storm. The overproduction of early response proin-
flammatory cytokines (tumor necrosis factor [TNF], inter-
leukin [IL]-6, and IL-1b) leads to vascular hyperpermeability
and multiorgan failure (3).
Besides inflammation, patients with COVID-19 are sus-
ceptible to the development of microthrombosis and dis-
seminated intravascular coagulation (4,5). Acute pulmonary
embolus has been reported in around 20% of severe COVID-
19 infections (6). Additionally, cerebral infarcts in multiple
vascular territories, as well as ischemia in the lower and
upper limbs, have been documented in patients with COVID-
19 (7). The initial coagulopathy of COVID-19 reveals a pro-
minent elevation of D-dimer and fibrin/fibrinogen degradation
products. Coagulation is activated by the inflammatory
response through several procoagulant pathways, resulting in
vascular endothelial injury (8).
In the face of the COVID-19 pandemic, patients undergoing
glucocorticoid (GC) therapy represent a highly vulnerable
group that could develop severe complications due to the
SARS-CoV-2 infection. We can classify patients receiving
GC therapy into two groups: 1) Patients with primary,
secondary and tertiary adrenal insufficiency (AI) receiving
GC replacement therapy; and 2) Patients receiving supraphy-
siological GC doses due to its potent anti-inflammatory and
immunosuppressive effects.
Cortisol is a glucocorticoid hormone synthesized and
secreted by the zona fasciculata of the adrenal gland cor-
tex. Under physiological situations, cortisol (called ‘‘stress
hormone’’) has the main function of preparing our body for a
‘‘fight or threat’’ reaction. Cortisol modulates the stress
response, blood glucose levels, blood pressure, immune sys-
tem, and inflammatory processes. Therefore, cortisol defi-
ciency leads to an altered innate immune cell response to
infection, increased production of inflammatory cytokines,
loss of the cortisol synergic action to maintain the vasopres-
sor effects of catecholamines, and decreased metabolic
energy (reduced gluconeogenesis and circulating free fatty
acids and amino acids) (9,10).
Adrenal insufficiency
AI is attributed to a failure of cortisol production by the
zona fasciculata of the adrenal cortex (primary AI or
Addison disease) or by a deficiency of adrenocorticotropin
hormone (ACTH, secondary AI) and/or corticotropin-releas-
ing hormone (CRH, tertiary AI). Primary AI is mainly caused
by autoimmune adrenalitis or infectious diseases (tubercu-
losis, paracoccidioidomycosis, HIV) (10,11). Hemorrhage orDOI: 10.6061/clinics/2020/e2022
Copyright & 2020 CLINICS – This is an Open Access article distributed under the
terms of the Creative Commons License (http://creativecommons.org/licenses/by/
4.0/) which permits unrestricted use, distribution, and reproduction in any
medium or format, provided the original work is properly cited.
No potential conflict of interest was reported.
Received for publication on May 12, 2020. Accepted for publication
on May 15, 2020
1
REVIEW ARTICLE
thrombosis are rare causes of primary AI, including thro-
mbocytopenia, Waterhouse-Friderichsen syndrome due to
meningococcemia, trauma, lupus erythematosus, antipho-
spholipid syndrome, panarteritis nodosa, and anticoagulant
therapy. Although microthrombosis and hypercoagulability
have been identified in COVID-19, an association with AI is
yet to be established.
Secondary AI is caused by tumors of the hypothalamic-
pituitary region or by their treatment with surgery or radio-
therapy. The most common cause of tertiary AI is the abrupt
cessation of high-dose GC therapy owing to the suppression
of the hypothalamic-pituitary-adrenal axis by chronic GC
administration (11). All individuals receiving a GC dose
comparable withX20 mg/day of prednisone for more than 2
weeks, or X5 mg of prednisone for more than 3-4 weeks, can
present suppression of ACTH/CRH release.
The major risk to patients with AI is the absence of normal
cortisol responses to stress. Patients with primary AI also
demonstrate aldosterone deficiency, which confers an addi-
tional risk to the adrenal crisis. All patients with AI should be
educated to increase (at least double) the GC replacement
dose during stress conditions (infections, trauma, surgery,
emotional stress) (11). However, most patients are often ext-
remely reluctant to follow these ‘‘sick day rules’’. In addition
to educational strategies, all patients with AI should maintain
an identification card stating the AI diagnosis, as well as the
recommendation of receiving 100 mg of hydrocortisone
intravenously in case of any medical emergency.
Adrenal crisis is a life-threatening medical condition and
remains an important cause of death in patients with AI (12).
Even in patients educated regarding appropriate measures in
stress conditions, an adrenal crisis is frequent (8.3 cases in 100
individuals with AI per year), with a mortality of 6% (13).
Adrenal crisis is defined as an acute deterioration in the health
status, associated with hypotension (systolic blood pressure
o100 mmHg) that resolves shortly after parenteral GC admi-
nistration (14). GC replacement therapy for AI consists of the
administration of 30 mg/day of hydrocortisone (20 mg early
morning and 10 mg at 2-3 pm) or 5-7.5 mg/day of prednisone.
Patients with secondary AI might require lower GC doses
(20 mg/day of hydrocortisone). Mineralocorticoid replace-
ment (0.05-0.1 mg/day of fludrocortisone) is indicated for
patients with primary AI. Patients with AI and symptoms of
COVID-19 should immediately double the dose of GC
replacement therapy.
During the COVID-19 pandemic, in the presence of any
emergency warning signs (such as trouble breathing, persis-
tent pain or pressure in the chest, confusion or cyanosis) or
an inability to administer oral GC doses, we recommend that
patients with AI should immediately seek an Emergency
service to determine the COVID-19 status and receive
100 mg hydrocortisone by intravenous injection, followed by
50 mg hydrocortisone intravenously every 6h or 200 mg/
day of hydrocortisone by continuous intravenous infusion.
Recently, it has been demonstrated using pharmacokinetic
parameters that a continuous intravenous hydrocortisone
infusion should be favored over intermittent bolus admin-
istration in the prevention and treatment of adrenal crisis
during major stress (15). The recommendations of GC therapy
for patients with AI and a suspected or confirmed COVID-19
diagnosis are listed in Table 1.
Patients using supraphysiological GC doses are at risk of
developing complications of COVID-19 owing to metabolic
and cardiovascular complications (hypertension, obesity, and
diabetes) associated with chronic GC therapy. If the under-
lying inflammatory or autoimmune disease is well control-
led, the GC dose should be tapered at the earliest. Patients
prescribed supraphysiological GC doses presenting any
emergency warning signs or an inability to administer the
oral medication should receive intravenous hydrocortisone,
based on the same recommendation as that for AI.
GC therapy for critically ill patients with COVID-19
Considering the inflammation and cytokine storm in
severe COVID-19, GC treatment for ARDS and septic shock
associated with SARS-CoV-2 infection has been debated. To
date, there is no published data available on the use of GC in
patients with COVID-19 and shock or ARDS. Therefore, a
recent recommendation by the European Society of Intensive
Care Medicine and the Society of Critical Care Medicine has
been based on indirect evidence from critically ill patients in
general (16).
A systematic review of 22 randomized controlled trials
comparing low-dose GC therapy versus no GC therapy in
adults with septic shock failed to demonstrate any significant
difference in mortality; however, length of ICU and hospital
stays were shortened with GC therapy (17). Moreover, the
Surviving Sepsis Campaign COVID-19 panel has sugges-
ted using intravenous hydrocortisone (200 mg) per day,
administered either as an infusion or intermittent doses,
for COVID-19 and refractory shock. In ARDS, evidence
of GC use is substantially conflicting because of mark-
edly heterogeneous etiologies and data (16). Finally, in the
case of mechanically ventilated adults with COVID-19 and
ARDS, several experts have preferred not to issue a
recommendation for GC use until higher-quality data are
available.
Table 1 - Recommendation of GC therapy for adrenal
insufficiency (AI) patients with suspected or confirmed COVID-19
diagnosis.
COVID-19 symptoms Glucocorticoid (GC) dose
Mild symptoms:
Fever, tiredness, dry cough,
aches and pains, nasal
congestion, runny nose,
sore throat, diarrhea.
Double GC dose as soon as symptoms
start:
- 40 mg hydrocortisone early
morning and 20 mg hydrocortisone
at 2-3 pm. Consider an additional
dose of 20 mg at night if severely
fatigued.
or
- 10 mg prednisone early morning.
Consider an additional dose of
2.5-5 mg at night if severely
fatigued.
- For patients with primary





pain or pressure in the chest,
confusion, or cyanosis.
- Hydrocortisone (100 mg) by
intravenous injection in bolus,
followed by
- Hydrocortisone (50 mg)
intravenously every 6h or 200 mg/
day by continuous intravenous
infusion.
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